Opthea Clinical Data of OPT-302 in Diabetic Macular Edema to be Presented at American Society of Retina Specialists 2020 Annual Meeting
July 23, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
June 09, 2020 19:23 ET
|
Opthea Limited
Primary endpoint of response with OPT-302 + Eylea® (aflibercept) achieved: 52.8% of refractory DME patients gained ≥ 5 letters of visual acuity at week 12 following OPT-302 combination therapy ...
Opthea to Host Investor Teleconference
June 08, 2020 20:37 ET
|
Opthea Limited
MELBOURNE, Australia, June 08, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2a clinical trial evaluating the safety and...
Opthea Completes Patient Dosing in Phase 2a DME Trial
March 30, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, March 30, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed...
Opthea to Present at the 9th Annual SVB Leerink Global Healthcare Conference
February 18, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today...
Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema
January 07, 2020 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed...
Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco
October 14, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
Opthea to Present at the Ophthalmology Innovation Summit in San Francisco
October 03, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress
September 06, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new...
Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINA
September 04, 2019 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that...